BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

Laura Shawver has joined Silverback Therapeutics Inc. as president, CEO and a director. Shawver, who succeeds Peter Thompson, was president and CEO of Synthorx Inc. until its $2.5 billion takeout in January by Sanofi (Euronext:SAN;...
BC Extra | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Oct 10, 2018
Politics & Policy

China adds insurance coverage for 17 cancer therapies

China's National Medical Insurance Administration added 17 cancer drugs to the National Reimbursement Drug List (NRDL) for coverage by the country's medical insurance program. The prices will go into effect by the end of October...
BC Extra | Aug 17, 2018
Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

China's State Medical Insurance Administration announced 18 cancer drugs that will be included in 2018 medical insurance access negotiations. Companies with drugs on the list will now enter into negotiations to include the drugs on...
BC Extra | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...
BC Extra | Mar 21, 2017
Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
BioCentury | Feb 25, 2017
Finance

Intranasal option

Canaan Partners sees a clear market opportunity for a non-invasive somatostatin analog, prompting the VC to lead a $25 million series A extension for Dauntless Pharmaceuticals Inc. The financing, announced Feb. 16, brings the round's...
BC Extra | Jan 14, 2017
Company News

Management tracks

Rare diseases company Swedish Orphan Biovitrum AB (SSE:SOBI) said CEO Geoffrey McDonough will leave the company on July 1. The company is searching for a replacement. The company also named Armin Reininger SVP and head...
Items per page:
1 - 10 of 63
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

Laura Shawver has joined Silverback Therapeutics Inc. as president, CEO and a director. Shawver, who succeeds Peter Thompson, was president and CEO of Synthorx Inc. until its $2.5 billion takeout in January by Sanofi (Euronext:SAN;...
BC Extra | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Oct 10, 2018
Politics & Policy

China adds insurance coverage for 17 cancer therapies

China's National Medical Insurance Administration added 17 cancer drugs to the National Reimbursement Drug List (NRDL) for coverage by the country's medical insurance program. The prices will go into effect by the end of October...
BC Extra | Aug 17, 2018
Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

China's State Medical Insurance Administration announced 18 cancer drugs that will be included in 2018 medical insurance access negotiations. Companies with drugs on the list will now enter into negotiations to include the drugs on...
BC Extra | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...
BC Extra | Mar 21, 2017
Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
BioCentury | Feb 25, 2017
Finance

Intranasal option

Canaan Partners sees a clear market opportunity for a non-invasive somatostatin analog, prompting the VC to lead a $25 million series A extension for Dauntless Pharmaceuticals Inc. The financing, announced Feb. 16, brings the round's...
BC Extra | Jan 14, 2017
Company News

Management tracks

Rare diseases company Swedish Orphan Biovitrum AB (SSE:SOBI) said CEO Geoffrey McDonough will leave the company on July 1. The company is searching for a replacement. The company also named Armin Reininger SVP and head...
Items per page:
1 - 10 of 63